Ulf Tedebark

Dr. Ulf Tedebark

orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 May 2024 in RSC Advances
Verified
Journal Article
Open access
PDF file
KKKristina Karalė
Kristina Karalė
MBMartin Bollmark
Martin Bollmark
AKAntanas Karalius
Antanas Karalius
MLMónica Lopes
Mónica Lopes
OPOswaldo Pérez
Oswaldo Pérez
UTUlf Tedebark
Ulf Tedebark
Synthesis and stability studies of BCN ON scaffolds used in SPAAC conjugations.

1 February 2014 in Nucleic Acid Therapeutics
Verified
Journal Article
Closed access
BBBurcu Bestas
Burcu Bestas
GMGraham Mcclorey
Graham Mcclorey
UTUlf Tedebark
Ulf Tedebark
PMPedro M.D. Moreno
Pedro M.D. Moreno
TRThomas Roberts
Thomas Roberts
OGOskar Gustafsson
Oskar Gustafsson
Targeting of pre-mRNA by short splice-switching oligonucleotides (SSOs) is increasingly being used as a therapeutic modality, one rationale being to disrupt splicing so as to remove exons containing premature termination codons, or to restore the translation reading frame around out-of-frame deletion mutations. The aim of this study was to investigate the effect of chemically linking individual SSOs so as to ascertain equimolar cellular uptake that would provide for more defined drug formulations. In contrast to conventional bispecific SSOs generated by conjugation in solution, here we describe a protocol for synthesis of bispecific SSOs on solid phase. These SSOs comprised of either a non-cleavable hydrocarbon linker or disulfide-based cleavable linkers. To assess the efficacy of these SSOs we have utilized splice switching to bypass a disease-causing mutation in the DMD gene concurrent with disruption of the reading frame of the myostatin gene ( Mstn ). The premise of this approach is that disruption of myostatin expression is known to induce muscle hypertrophy and so for Duchenne muscular dystrophy (DMD) could be expected to have a better outcome than dystrophin restoration alone. All tested SSOs mediated simultaneous robust exon removal from mature Dmd and Mstn transcripts in myotubes. Our results also demonstrate that using cleavable SSOs is preferred over the non-cleavable counterparts and that these are equally efficient at inducing exon skipping as cocktails of monospecific versions. In conclusion, we have developed a protocol for solid-phase synthesis of single molecule cleavable bispecific SSOs that can be efficiently exploited for targeting of multiple RNA transcripts.

17 November 2021 in Molecules
Verified
Journal Article
Open access
PDF file
KKKristina Karalė
Kristina Karalė
MBMartin Bollmark
Martin Bollmark
RSRouven Stulz
Rouven Stulz
DHDmytro Honcharenko
Dmytro Honcharenko
UTUlf Tedebark
Ulf Tedebark
RSRoger Stromberg
Roger Stromberg
2′-O-(N-(Aminoethyl)carbamoyl)methyl-modified 5-methyluridine (AECM-MeU) and 5-methylcytidine (AECM-MeC) phosphoramidites are reported for the first time and prepared in multigram quantities. The syntheses of AECM-MeU and AECM-MeC nucleosides are designed for larger scales (approx. 20 g up until phosphoramidite preparation steps) using low-cost reagents and minimizing chromatographic purifications. Several steps were screened for best conditions, focusing on the most crucial steps such as N3 and/or 2′-OH alkylations, which were improved for larger scale synthesis using phase transfer catalysis (PTC). Moreover, the need of chromatographic purifications was substantially reduced by employing one-pot synthesis and improved work-up strategies.